An introduction to the Marburg virus vaccine consortium, MARVAC.
Robert W CrossIra M LonginiStephan BeckerKarin BokDavid BoucherMiles W CarrollJanet V DíazWilliam E DowlingRuxandra Draghia-AkliJames T DuworkoJohn M DyeMichael A EganPatricia FastAmy FinanCourtney FinchThomas R FlemingJoan FuscoThomas W GeisbertAnthony GriffithsStephan GüntherLisa E HensleyAnna HonkoRuth HunegnawJocelyn JakubikJulie LedgerwoodKerstin LuhnDemetrius MatassovJeffrey MeshulamEmily V NelsonChristopher L ParksRoxana RustomjeeDavid SafronetzLauren M SchwartzDean SmithPaul SmockYdrissa SowChristina F SpiropoulouNancy J SullivanKelly L WarfieldDaniel WolfeCourtney WoolseyRoland ZahnAna María Henao-RestrepoCésar Muñoz-FontelaAndrea MarziPublished in: PLoS pathogens (2022)
The emergence of Marburg virus (MARV) in Guinea and Ghana triggered the assembly of the MARV vaccine "MARVAC" consortium representing leaders in the field of vaccine research and development aiming to facilitate a rapid response to this infectious disease threat. Here, we discuss current progress, challenges, and future directions for MARV vaccines.
Keyphrases